Re-Rechallenge 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

Abstract

¹⁷⁷Lu-PSMA-617 radioligand therapy has been US Food and Drug Administration–approved safe and effective treatment modality for metastatic castration-resistant prostate cancer, usually administered in 4 to 6 cycles at 6 to 8 weeks apart. Many patients achieve partial response or stable disease with biochemical response after treatment. However, these effects are usually short-lived, and patients ultimately show disease progression after a median period of 6 to 9 months. Rechallenge therapy appears to be safe and effective treatment modality in such patients. We show the clinical efficacy and safety of re-rechallenge ¹⁷⁷Lu-PSMA radioligand therapy in a 64-year-old man with metastatic castration-resistant prostate cancer with disease progression on multiple lines of hormonal and chemotherapy treatment.